Suchergebnisse
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $1.05 per share a year ago. These figures
Urogen Pharma Q2 Earnings Call Highlights
Key Points
- Interested in Urogen Pharma? Here are five stocks we like better.
- Revenue surged to $72.5 million in the second quarter, up from $24.2 million a year earlier, driven by ZUSDURI net
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even
Progen Pharmaceuticals Ltd
WKN: A2AD8F / Symbol: PGLA / Name: Progen Pharma / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
Karo Pharma AB
WKN: A14YW4 / Symbol: KARO / Name: Karo Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
Inovio Pharma
WKN: A115GK / Symbol: INO / Name: Inovio Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
Innate Pharma
WKN: A0LCUJ / Name: Innate Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
4d Pharma plc
WKN: A1XD45 / Name: 4D Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
aTyr Pharma Inc
WKN: A2PM86 / Name: aTyr Pharma / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
ESSA Pharma Inc
WKN: A2JKQ4 / Name: ESSA / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
Evgen Pharma plc
WKN: A142UC / Name: Evgen Pharma / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
